| The Mary Kay Foundation |
2013 Cancer Grant Recipients  | YSF Board Member Analisa DiFeo, Ph.D., Case Western Reserve University, Cleveland, OH Title of Project: Single Agent Dual Inhibition of the AKT and ERK Signaling Pathway for the Treatment of Ovarian Cancer | |
| |
 | David K. Ann, Ph.D., City of Hope, Los Angeles, CA Title of Project: Targeting Arginime Dependency, A metabolic Achilles’ Heel for Breast Cancer |
| |
 | Alexander S. Brodsky, Ph.D., Brown University, Providence, RI Title of Project: New Approaches to Target Mevalonate Biosynthesis for Ovarian Cancer |
| |
 | Kathleen Cho, Ph.D., University of Michigan, Ann Arbor, MI Title of Project: Examining falopian tube origin of high grade serous “ovarian” carcinoma |
| |
 | Dipanjan Chowdbury, Ph.D., Dana-Farber Cancer Institute, Boston, MA Title of Project: MicroRnas as a Molecular Basis for Defective Homologous Recombination in Epithelial Ovarian Cancer |
| |
| |
| |
 | Andrew J. Ewald, Ph.D., Johns Hopkins University, Baltimore, MD Title of Project: Basal marker+ cancer cells lead collective invasion and dissemination across multiple subtypes of breast cancer |
| |
 | Liza Makowski, Ph.D., UNC Chapel, Chapel Hill, NC Title of Project: Reversing carcinogenic effect of obesity on basal-like breast cancer |
| |
 | Michael G. Rosenfeld, MD, University of California, San Diego, CA Title of Project: Reprogramming Breast Cancer Cells |
| |
 | Joy Y. Wu, Ph.D., Stanford University, Palo Alto, CA Title of Project: Effects of Parathyroid Hormone on the Breast Cancer Metastatic Niche in Bone |
| |
 | Gerburg M. Wulf., Ph.D., Beth Israel Deaconess Medical Center, Boston, MA Title of Project: Use of P13Kinase inhibitors to improve the Outcomes of Antineoplastic Treatments for Breast Cancer |
